CME Background Information

Release, Review, and Expiration Dates

The 2012 NCDEU Poster Session was published in June 2012 and is eligible for AMA PRA Category 1 Credit™ through December 31, 2012. The latest review of this material was May 2012.

To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.

Objective

After completing this educational activity, you should be able to:

Statement of Need and Purpose

This special 2012 NCDEU Poster Session was developed based on our assessment of the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on current research relevant to clinical practice.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Financial Disclosure

The presenters for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal financial relationships between themselves and their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Financial disclosures from the presenters are as follows:

Dr Achtyes has received grant/research support from Novartis.

Dr Charney and Mount Sinai School of Medicine have been named on a use-patent of ketamine for the treatment of depression. If ketamine were shown to be effective in the treatment of depression and received approval from the Food and Drug Administration for this indication, Dr Charney and Mount Sinai School of Medicine could benefit financially.

Dr Furmaga has received grant/research support from AssureRx Health, Priority Health, and the Pine Rest Foundation.

Dr Iosifescu is a consultant for CNS Response.

Dr IsHak has received grant/research support from NARSAD and Pfizer.

Dr Lapidus is a consultant for LCN Consulting.

Dr Lavretsky has received grant/research support from Forest and Eli Lilly.

Drs Cohen, Cole, Ha, Miller, Murrough, Nelson, Perez, Sayer, and Soleimani; Mr Alves, Mr Christensen, and Mr Nguyen; and Ms Eskin, Ms Pillemer, Ms Smart, and Ms Stern have no personal affiliations or financial relationships with any commercial interest to disclose relative to this presentation.

Disclosure of Off-Label Usage

In this 2012 NCDEU Poster Session, participants may be presenting investigational information about pharmaceutical agents that is outside US Food and Drug Administration–approved labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Review Process

This 2012 NCDEU Poster Session has been reviewed for accuracy and fair balance by a selection committee of the American Society of Clinical Psychopharmacology (ASCP).

Acknowledgment

This 2012 NCDEU Poster Session is derived from the 52nd Annual NCDEU Meeting, which was held May 29–June 1, 2012, in Phoenix, Arizona, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., the National Institute of Mental Health (NIMH), and the ASCP. The opinions expressed herein are those of the presenters and do not necessarily reflect the opinions of the CME provider and publisher, the NIMH, or the ASCP.